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The intersecting HIV and Tuberculosis epidemics in countries with a high disease burden of both infections pose many challenges
and opportunities. For patients infected with HIV in high TB burden countries, the diagnosis of TB, ARV drug choices in treating
HIV-TB coinfected patients, when to initiate ARV treatment in relation to TB treatment, managing immune reconstitution,
minimising risk of getting infected with TB and/or managing recurrent TB, minimizing airborne transmission, and infection
control are key issues. In addition, given the disproportionate burden of HIV in women in these settings, sexual reproductive
health issues and particular high mortality rates associated with TB during pregnancy are important. The scaleup and resource
allocation to access antiretroviral treatment in these high HIV and TB settings provide a unique opportunity to strengthen both
services and impact positively in meeting Millennium Development Goal 6.
1.Introduction
Infection with Mycobacterium tuberculosis (MTB) remains
one of the leading causes of morbidity and mortality globally
[1]. The growing burden of multidrug-resistant (MDR) and
extremely drug-resistant (XDR) cases of tuberculosis (TB)
poses additional challenges to TB case management. Of the
estimated 9.3 million new cases of TB that occurred in 2007,
1.37million (15%) were co-infected with HIV. Sub-Saharan
Africa accounted for 79% of the burden of TB-HIV co-
infections, followedby South-EastAsia (11%). In 2007, there
were456,000TB-relateddeathsamongHIV-positivepatients
accounting for 23% of the global HIV/AIDS mortality [2].
Globally, an estimated 33 million people are infected with
HIV. HIV-positive people are about 20 times more likely
than HIV-negative people to develop TB in countries with
a generalized HIV epidemic [2]. Although South Africa is
home to <1% of the global population, it accounts for 17%
of the global burden of HIV infection and approximately
one quarter of all HIV-TB co-infected patients [2, 3].
TB co-infection in HIV-infected pregnant women is
emerging as a major non-obstetric cause of maternal deaths
in sub-Saharan Africa [4]. According to data from two
studies at a major tertiary hospital in KwaZulu-Natal (the
epicenter of the pandemic), Khan et al. [5] in 2001 demon-
strated a 32-fold increased risk of death among TB-HIV co-
infected pregnant women compared to those without HIV-
infection, and Ramogale et al. [6] in 2007 reported that the
majority of deaths among HIV-infected pregnant women
were associated with TB co-infection. TB is also a major
cause of morbidity in HIV-infected children, with HIV-
infected children having a 20–25-fold higher incidence of TB
than HIV-uninfected children, with an overall TB incidence
in South African HIV-infected children of 9.2% (95% CI:
0.14–0.97) [7–9].
The intersection of the TB and HIV epidemics and the
challenges and opportunities they provide for addressing
both epidemics is the focus of this paper.
2.DiagnosingTBinHIV-InfectedPatients
TB is the most common presenting opportunistic infection
amongHIV-infectedpatients,whoremainathighriskforTB2 Clinical and Developmental Immunology
throughout the course of their disease. HIV-infected patients
on HAART have a TB incidence rate of 4.6 cases/100 patient-
years, approximately 10-fold higher than TB incidence rates
in HIV-negative patients in the same community [10].
Early identiﬁcation of TB suspects, with prompt triage
into TB diagnostic and treatment services, are beneﬁcial in
improving overall clinical outcomes in co-infected patients,
as well as in reducing TB transmission from undiagnosed
and untreated patients. Additionally, HIV-infected patients
who screen negative for TB can be assessed for eligibility
for isoniazid (INH) preventive therapy. Notwithstanding
these beneﬁts, HIV-TB co-infected patients have a higher
frequency of smear negative TB sputum tests [11]a n da r e
four times more likely to have extra-pulmonary TB and
atypical as well as nonspeciﬁc radiologic features of TB.
Thus, clinical diagnosis of pulmonary tuberculosis (PTB) in
patients co-infected with HIV remains a challenge especially
in settings where there are limited clinicians and radiological
facilities to conﬁrm a TB diagnosis [12–14]. Further, HIV-
TB co-infected patients have varied clinical presentation of
TB, ranging from the classic signs of TB infection of cough,
weight loss, fever, and drenching night sweats to nonspeciﬁc
signs and symptoms [15, 16]. Diagnosis of drug-resistant
TB remains a challenge in many high-burden TB settings,
largely as a result of a combination of poor laboratory
capacity and the absence of widespread programmatic drug
susceptibility testing. Mortality rates in excess of 80% have
been reported for patients with HIV and XDR-TB, in the
context of an XDR-TB outbreak, and have been attributed to
diagnostic delays and lags in instituting appropriate therapy
[17]. Recent years have seen an investment of research
eﬀort into developing new assays with increased sensitivity
and speciﬁcity, shorter turn-around times, with greater
suitabilityforhighburdenresource-constrainedsettings,and
potentialvalueinHIV-infectedindividuals(Table 1).Astudy
by Dheda et al. [18], showed urine-LAM positivity to be
signiﬁcantly associated with HIV positivity (P = .007), with
sensitivity signiﬁcantly higher in HIV-infected compared to
uninfected patients (P = .001), and in HIV-infected partici-
pants with a CD4 < 200cells/mm3, compared to those with
CD4 counts above 200 (P = .003). In this particular study,
urine-LAM remained highly speciﬁc for TB both in HIV-
uninfected and in HIV-infected patients irrespective of CD4
counts. Twenty-ﬁve percent of smear-negative but culture-
positive HIV-infected patients with a CD4 < 200cells/mm3
were positive for urine-LAM [18]. It is important to note
that T-cell-based assays such as the interferon gamma release
assays, which include the T-Spot-TB and QFT Gold-in-tube,
arenotusefulinthediagnosisofactiveTBbecausethesetests
do not distinguish between latent and active TB.
3.EnhancingTBDiagnosisinHIV-Infected
Patients and Knowledge of HIV Status in TB
Patients and Prophylactic Use of Isoniazid
To overcome diagnostic infrastructure and human resource
constraints, a TB symptom screening questionnaire is
increasingly being utilised to more eﬀectively and eﬃciently
screen for TB [26]. Data from nine ICAP ARV treatment
initiation sites in the Eastern Cape, where infrastructure
and human resource capacity are extremely limited have
provided compelling evidence for the utility of this screening
tool. ARV treatment sites can utilise this screening tool to
maximise opportunities for TB screening in HIV-infected
patients and TB services can include provider-initiated
counselling and testing (PIT) services to increase knowledge
of HIV status in TB patients, linked to CD4 testing and/or
clinical staging of HIV disease in patients testing HIV
positive,andpotentiallyprovideearlieraccessintoAIDScare
and treatment services [27]. The World Health Organization
(WHO) currently recommends PIT as a standard of care for
allpatientswithsignsandsymptomsofTB[28].SouthAfrica
has, since the 1st April 2010, taken this a step further and
now emphasises HIV counselling and Testing (HCT) as part
of opportunistic health promotion [29]. Given that South
Africa has an HIV TB co-infection rate that exceeds 69%,
this is a signiﬁcant policy shift for enhancing HIV survival
and impacting the TB epidemic in this setting [30].
4. IntegrationofHIV,TB,andMDR-TBServices
Though intertwined, HIV and TB are treated in separate
programs and facilities. TB clinics have been slow to imple-
mentHIVcareandtheintroductionofantiretroviraltherapy
(ART), which has resulted in the establishment of separate
HIV clinics, that often do not focus on TB co-infection
[31, 32]. In countries with dual HIV-TB epidemics, the
provision of HIV testing to TB patients and the provision of
CD4+ count assays to those who test HIV-positive are a cost-
eﬃcient approach in identifying co-infected patients in need
of ART [31]. One strategy to improve outcomes for HIV-TB
patients is to utilize existing TB-care facilities and combine
HIV care with TB care. TB clinics already have an established
infrastructure, drug, and patient management systems.
Treatment of both diseases requires addressing adherence
to therapy and monitoring for side eﬀects, toxicities, and
treatment failure. Up until early 2010, uncertainty existed as
to the best time to initiate HAART in HIV TB co-infected
patients. Issues of high mortality rates in co-infected patients
not initiated on ART were oﬀset by concerns of concomitant
treatment of both diseases including increased frequency
of immune reconstitution inﬂammatory syndrome (IRIS);
potential interaction between rifampicin and NNRTI and PI
drugs; pill burden, adherence, and overlapping toxicity. Data
from the Starting Antiretroviral Therapy at Three Points in
Tuberculosis (SAPiT) trial provided empiric evidence for
integration of HIV and TB care, with a reduction in all-
cause mortality of 56% among co-infected patients with
CD4+ counts< 500 that integrated HIV and TB treatment
compared to those that deferred ART initiation until after
TB treatment was complete. Additionally, patients that had
integrated HIV and TB treatment had both favourable TB
outcomes and reduced incidence of IRIS. The question of
whether the most optimal time to initiate ART is during
the intensive or continuation phase of TB treatment remains
unanswered [33]. Thus far, studies have demonstrated
poorer MDR-TB and HIV treatment outcomes in duallyClinical and Developmental Immunology 3
Table 1: Newer Diagnostic Technologies for TB.
Technology Turnaround time Sensitivity gain References
Ziehl Neelsen 2-3 days
[19]
Solid Culture 30–60 days Baseline
Liquid Culture 15–30 days +10%
Rapid Speciation Compared to LJ
Line Probe Assay 1st line Rif and INH (e.g.,
INNOLiPA Rif.TB and the GenoTyp MTBDR) 2–4 days Currently smear positive only [20, 21]
Integrated Nucleic Acid Ampliﬁcation Tests
(INH and Rif only) GeneXpert MTB/RIF 90 minutes +40% compared to ZN [22]
The Microscopic-Observation
Drug-Susceptibility (MODS) 7 Days +14% compared to LJ [23]
T-cell-based Assays (Interferon-γ-based assays) 16–24 hrs
(if not batch run)
Overall sensitivity gain unknown Sensitivity:
76% for QTF-G, and 90% for Elispot, unable
to distinguish latent from and active TB, role in
HIV infection uncertain
[24]
LED-based Flourescent Microscopy 1-2 days +10% Compared to ZN [19]
TB Antigen Detection (Lipoarabinomannan
–LAM Assay)
3-4 hours
Point of care testing
available soon
Overall sensitivity gain unknown 52%
sensitivity in HIV+ patients, speciﬁcity 89%
[18, 25]
infected patients. MDR-TB HIV co-infection has been
described as the “perfect storm”, as it is associated with
extremely high mortality and lack of adequate second line
anti-TB therapy. Complexities in managing MDR-TB in
HIV include the availability of rapid drug susceptibility
testing, prevention of nosocomial transmission to patients
and HCW, potentiated drug toxicity, ART drug interactions
with MDR-TB treatment, and a high pill burden [34, 35].
Publications from South Africa by O’Donnell et al. [36]a n d
Dheda et al. [17] have demonstrated improved outcomes
with the integration of antiretroviral therapy with MDR
and XDR therapies, with respect to overall reduction in
mortality rates and better outcomes in co-infected patients
that integrated therapies for HIV and drug-resistant TB.
5. Immune Reconstitution Inﬂammatory
Syndrome (IRIS)
TB IRIS results from either deterioration of TB while on
anti-TB treatment, known as paradoxical TB IRIS, or a
new presentation of previously subclinical TB referred to
as unmasking TB IRIS. Mycobacteria account for approx-
imately 40% of all cases of infective IRIS in patients
initiated on ART [37–41]. The frequency of paradoxical
TB-IRIS range from 8% to 43% [42–45] and is dependent
on background TB prevalence rates. In contrast, literature
describing the prevalence and presentation of unmasking
TB IRIS is more limited [46–48]. The common consensus
from clinical studies suggests that low CD4+ cell counts are
associated with an increased incidence of IRIS [49, 50]. The
introduction of ART early in TB treatment is an additional
risk factor for IRIS. A South African study indicated a 12%
overall incidence of TB IRIS in HIV-TB co-infected patients,
with an IRIS incidence of 32% when ART was initiated
within 2 months of TB diagnosis and an IRIS incidence of
70% if ART was initiated within a month of starting TB
therapy [51]. A meta-analysis of IRIS studies by Muller et al.
[50] suggests that both frequency of IRIS events and the high
early mortality in ART programs in resource-limited settings
could be prevented by starting ART earlier prior to the risk
of opportunistic infections.
6.ProphylaxisinHIV-TBCo-InfectedPatients
Data from the Development of AntiRetroviral Therapy in
Africa (DART) trial have demonstrated that cotrimoxazole
prophylaxisreducedmortalityinpatientswithHIVinfection
on ART for up to 72 weeks regardless of CD4 count
status, with mortality similarly reduced in patients with a
current CD4 cell counts above and below 200 cells/μL[ 52].
Notwithstanding the absence of deﬁnitive evidence from
randomised controlled trials on optimal duration of IPT
in HIV-infected patients, data from several observational
studies demonstrate that INH Preventive Therapy (IPT) is
bothcosteﬀectiveandbeneﬁcial[53–55]throughcombating
low bacillary load latent TB which serves as a reservoir for
possible recurrent disease [56].
Concurrent administration of ART and IPT has demon-
strated a TB risk reduction of 76–89% in observational
studies from both South Africa and Brazil [54, 55]. Given
the challenges in diagnosing TB in HIV-infected patients,
the potential of unintentionally treating active TB with
monotherapy and thereby contributing to drug resistance
is very real especially in settings with inadequate sputum,
radiology, and tuberculin skin testing resources for the
exclusion of active TB [57]. Signiﬁcantly, despite the need to
exclude active TB prior to the administration of IPT, many
people die of TB without having received either IPT or any
appropriate treatment for their unrecognised TB [58].4 Clinical and Developmental Immunology
The protection oﬀered by IPT to those infected with
HIV may depend on a number of factors including degree
of immune suppression of the individual, duration of IPT,
adherence to and potency of the regimen, as well as the
general risk of reinfection in that setting [56, 59]. Data
from randomised controlled trials using 6–12 month IPT
in HIV positive patients demonstrate reductions in risk of
active TB by about a third compared to those on placebo,
with reductions of up to two-thirds in those who tested
tuberculin skin test (TST) positive [56, 57, 60]. Additionally,
a Botswana trial that initiated 1,006 patients on continuous
IPT demonstrated that IPT was 92% eﬀective in reducing
TB in TST-positive patients [61]. An analysis of published
studies on the treatment of latent TB infection by Akolo et
al. [62] demonstrated that TST negative individuals seem
not to beneﬁt from IPT. While more studies are required to
establish optimal duration of IPT in HIV-infected patients
in high-burden TB settings, current data suggest optimal
beneﬁt from IPT when used for a period of 9 months post
TB therapy [63]. Current recommended dosages for IPT
include 300mg daily for 6–9 months in adolescents and
adults or alternatively 800–900mg twice weekly if supervised
treatment is feasible [64–67].
WhiletoxicityfromcoadministrationofIPTandHAART
is valid, the likelihood of stopping therapy as a result of
adverseeventshastodatebeenlow.Theriskofadverseevents
was higher with rifampicin and pyrazinamide-containing
regimens than INH monotherapy [56]. The feasibility of
implementing IPT into HIV care programmes has been
demonstrated in many African settings [27]. INH adherence
education and motivation, with monitoring of ongoing
adherence and toxicity can be readily integrated into HIV
care programmes. There are several beneﬁts of instituting
IPT to patients in HIV wellness and pre-ART readiness
programmes, including protection from TB-associated mor-
bidity and mortality, and the incentive for regular clinic
attendance for patients.
7. RecurrentTB
Recurrent TB accounts for the majority of TB cases in
countries with a high TB incidence rate [2]w i t hH I V
infection a major risk factor for TB recurrence [68–70].
The WHO Guidelines deﬁnes recurrent TB as the diagnosis
of active TB in patients previously treated for TB and
were subsequently declared cured or whose treatment was
completed. Data from South Africa indicate an association
between high TB incidence and ART initiation at CD4 <
200cells/mm3 or at WHO Stage 4 HIV disease [71]. HIV-
infected patients on HAART have a TB incidence rate of
4.6 cases/100 patient-years, approximately 10-fold higher
than the TB incidence rates of HIV-negative patients in the
same community. A study of South African gold miners
demonstrated that TB recurrence was 5 times more likely
in HIV-positive patients [72]. The “risk of TB relapse”
remains a signiﬁcant factor in determining optimal duration
of anti-TB therapy. Current guidelines suggest a 6-month
rifamycin-based regimen as suitable irrespective of HIV
status, yet to date, two randomized clinical trials suggest
otherwise [73, 74]. One RCT compared 12-month standard
rifampin-based regimen to a 6-month regimen and found
lower recurrence rates at 18 months in the group with
an extended TB therapy duration [74]. The second RCT
which compared standard short course therapy in both
HIV-infected and uninfected groups showed that rates of
recurrence in HIV-infected individuals were only reduced
when combined with 1 year of continued INH therapy
post short-course TB therapy completion [73]. Of note, is
that both trials predated the ART era. There is a paucity
of data on incidence rates and risk factors for recurrent
TB in an HIV-infected population on ART. TB scarring,
cavities, regimens used for the initial episode, and a low
CD4 count are some risk factors associated with recurrent
TB. There has been considerable interest in the timing of
HAARTanditscapacityforimmunerestoration.Irrespective
of the level of TB burden in diﬀerent settings, HAART
has consistently been shown to substantially reduce the
risk of TB within HIV cohorts by 70–90%. It is, however,
hypothesised that partial immune restoration resulting from
ART creates a persistently heightened risk for recurrent
TB [75, 76], which is in contrast to the role of HAART
in community TB control, as patients on HAART survive
longer, yet they remain at a chronic heightened risk for
TB infection [77]. With increasing numbers of patients
on ART spending long hours in inadequately ventilated
waiting rooms in AIDS clinics and where limited infection
control activities are implemented, the impact of recurrent
TB especially with drug-resistant TB needs to be urgently
investigated. Scaleup of ART services remains an essential
strategy in TB control. Declining incidence density rates of
TB in the ﬁrst ﬁve years of HAART have been demonstrated
byLawnetal.However,patientswithCD4<100cells/mland
more advanced pretreatment immune suppression remain at
heightened risk for recurrent TB [77].
8. Enhancing Infection Control for
TB inARVClinics
GiventhehighratesofundiagnosedTBinAIDSpatientsand
the excess mortality associated with HIV-TB co-infection,
HIV clinics should pay particular attention to infection
control including good ventilation to minimise further TB
risk acquisition in AIDS patients. The Tugela Ferry XDR-TB
outbreak in rural South Africa brought to public attention
the consequences of nosocomial TB transmission in high
HIV burden settings and has also highlighted the risk of
acquiring multi-drug-resistant TB in health care workers
and in the general public. A 3-tier approach for TB-infection
control has been developed by the WHO for application in
all settings and includes administrative and environmental
controls and personal protection. The proposed
interventions are simple and feasible and can be customised
further based on available resources [78]. Administrative
controls include (i) early identiﬁcation and separation
of infectious patients, (ii) controlling infectiousness by
educatingpatients onpropercoughetiquette andrespiratory
hygiene, and (iii) limiting time patients spend in health care
facilities through decreasing hospital stays and increasingClinical and Developmental Immunology 5
outpatient TB treatment [79]. Environmental controls
include (i) encouraging natural and mechanical ventilation
and (ii) upper-room ultraviolet light. Natural ventilation
could be as simple as opening a window and a door to create
cross ventilation. However, mechanical ventilation can be
complicated and expensive as the installation of split vent
cooling and air exchange systems, or as simple as installing
ceiling and upright fans. UV light, if installed properly, has
been shown to damage the MTB organism without causing
harm to patients [80–82]. Low-cost sputum booths are
increasingly being erected within clinics as an environmental
infection control measure in high burden TB settings
[83]. Personal measures include (i) staﬀ use of particulate
respirators such as the N95 respirator though eﬀectiveness is
dependent on staﬀ compliance, additional training, as well
as ﬁt testing in ensuring proper use and (ii) provision of
surgical masks for patients to create a mechanical barrier to
the spread of infectious droplet nuclei [84–86].
9. Conclusion
Much has been learnt about HIV-related TB and much
remains to be learnt. Research eﬀorts need to focus on pro-
tective TB vaccines for immuno-compromised populations,
newﬁrst-andsecond-lineTBdrugs,pointofcarediagnostics
for TB and TB IRIS, including strategies to optimise clinical
outcomes in patients co-infected with HIV, and drug-
resistant TB. The intersection of the HIV and TB epidemics
provides a unique opportunity to strengthen TB and HIV
serviceswithsubstantialmorbidityandmortalitygainsatthe
individual and population level. This level of public health
beneﬁt in the current ﬁscal climate and growing disease
burden is critically important. The integration of HIV and
TB services could serve as an important role model for other
service delivery. Signiﬁcantly, reducing and better managing
TB in HIV-infected persons could make a substantial
contribution to countries reaching their MDG health goals.
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